Guideline Panel Meeting: Upper Tract Urothelial Carcinoma (UTUC) (2022)
Panel members will be reviewing evidence prepared and presented by a methodologist who has been extracting and analyzing data from research articles. The panelists will inquire about aspects of the evidence and the methodologists will provide explanations. The panel will discuss the evidence and deliberate on the best practice methods to diagnose and treat UTUC.
This activity is limited to UTUC Guidelines Panel Members only.
After completing this activity, participants will be able to:
- Analyze the latest scientific evidence for the diagnosis and management of UTUC.
- Recommend appropriate diagnostic and treatment options for UTUC.
- Apply improved critical thinking skills to medical literature reviews.
Wednesday, October 5, 2022
11:00am Welcome & Introductions Brooke Bixler
11:10am Conflict of Interest Disclosures and Panel Responsibilities Brooke Bixler
11:20am UTUC Evidence Overview Dr. Roger Chou
Wednesday, October 19, 2022
9:00am Welcome Brooke Bixler
9:10am Conflict of Interest Disclosures and Panel Responsibilities Brooke Bixler
9:20am Statement Review Panel
11:30am Continue Statement Discussion Panel
1:00pm Next Steps Brooke Bixler
Thursday, October 20, 2022
7:00pm Statement Review Panel
9:00pm Next Steps Brooke Bixler
The Upper Tract Urothelial Carcinoma (UTUC) Guidelines Panel have the following disclosures.
|Name||Company Name||Relationship Type||Financial||End Date|
|Chang, Sam S.||NIH||Scientific Study or Trial||Yes||Current|
|Chang, Sam S.||GLG||Consultant or Advisor||Yes||Current|
|Chang, Sam S.||Janssen||Consultant or Advisor||Yes||Current|
|Chang, Sam S.||BMS||Consultant or Advisor||Yes||Current|
|Chang, Sam S.||pfizer||Consultant or Advisor||Yes||Current|
|Chang, Sam S.||urogen||Consultant or Advisor||Yes||Current|
|Chang, Sam S.||Uro Today||Health Publishing||Yes||Current|
|Chang, Sam S.||virtuoso surgical||Consultant or Advisor||Yes||Current|
|Chang, Sam S.||mIR||Consultant or Advisor||Yes||Current|
|Chang, Sam S.||Prokarium||Consultant or Advisor||Yes||Current|
|Chang, Sam S.||KDx Diagnostics||Consultant or Advisor||No||Current|
|Chang, Sam S.||Tu Therapeutics||Consultant or Advisor||Yes||Current|
|Clark, Peter Earl||Galil Medical||Consultant or Advisor||No||01/11/2022|
|Clark, Peter Earl||Merck||Consultant or Advisor||Yes||06/01/2022|
|Coleman, Jonathan Andrew||Steba||Scientific Study or Trial||No||09/30/2021|
|Coleman, Jonathan Andrew||Angiodynamics||Scientific Study or Trial||No||Current|
|Coleman, Jonathan Andrew||Metabolon||Scientific Study or Trial||No||Current|
|Hoffman-Censits, Jean H.||Roche Genentech||Health Publishing||Yes||Current|
|Hoffman-Censits, Jean H.||Seattle Genetics||Consultant or Advisor||Yes||Current|
|Hoffman-Censits, Jean H.||Foundation Medicine||Consultant or Advisor||Yes||Current|
|Hoffman-Censits, Jean H.||Astra-Zeneca||Consultant or Advisor||Yes||Current|
|Hoffman-Censits, Jean H.||Uro-gen||Other-I accepted then declined this event - this should be deleted as COI please||Yes||11/16/2021|
|Hoffman-Censits, Jean H.||Genentech||Scientific Study or Trial||Yes||Current|
|Kulkarni, Girish S.||Janssen||Consultant or Advisor||Yes||Current|
|Kulkarni, Girish S.||Merck||Consultant or Advisor||Yes||Current|
|Kulkarni, Girish S.||Ferring||Consultant or Advisor||Yes||Current|
|Kulkarni, Girish S.||Astra Zeneca||Scientific Study or Trial||Yes||Current|
|Kulkarni, Girish S.||Theralase||Consultant or Advisor||Yes||Current|
|Kulkarni, Girish S.||Abbvie||Consultant or Advisor||Yes||Current|
|Kulkarni, Girish S.||Roche||Consultant or Advisor||Yes||Current|
|Kulkarni, Girish S.||Bristol Myers Squibb||Scientific Study or Trial||Yes||Current|
|Kulkarni, Girish S.||Merck||Scientific Study or Trial||Yes||Current|
|Kulkarni, Girish S.||Theralase||Scientific Study or Trial||Yes||Current|
|Kulkarni, Girish S.||TerSera||Consultant or Advisor||Yes||Current|
|Kulkarni, Girish S.||Verity Pharmaceuticals||Scientific Study or Trial||Yes||Current|
|Kulkarni, Girish S.||EMD Serano||Consultant or Advisor||Yes||Current|
|Kulkarni, Girish S.||Bladder Cancer Canada||Leadership Position||No||Current|
|Matin, Surena Fazeli||Ology Education Resources||Meeting Participant or Lecturer||Yes||10/28/2020|
|Matin, Surena Fazeli||Johnson&Johnson||Consultant or Advisor||Yes||05/16/2023|
|Matin, Surena Fazeli||Clinical Care Options||Meeting Participant or Lecturer||Yes||09/11/2021|
|Matin, Surena Fazeli||Merck||Consultant or Advisor||Yes||Current|
|Matin, Surena Fazeli||QED||Other-Clinical trial sponsor||Yes||Current|
|Pierorazio, Phillip M.||Testicular Cancer Awareness Foundation||Leadership Position||No||Current|
|Pierorazio, Phillip M.||National Comprehensive Cancer Network||Consultant or Advisor||No||09/01/2021|
|Pierorazio, Phillip M.||Urogen Pharmaceuticals||Consultant or Advisor||Yes||07/01/2021|
|Pierorazio, Phillip M.||Wolters Kluwer||Health Publishing||Yes||Current|
|Pierorazio, Phillip M.||Ethicon (J&J)||Consultant or Advisor||Yes||Current|
|Potretzke, Aaron Mark||Status: Nothing to disclose|
|Psutka, Sarah P.||Merck||Consultant or Advisor||Yes||08/31/2021|
|Psutka, Sarah P.||Bladder Cancer Advocacy Network||Other-Research Grant Funding||Yes||08/31/2021|
|Raman, Jay D.||American Kidney Stone Management||Investment Interest||Yes||Current|
|Raman, Jay D.||MDx Health||Scientific Study or Trial||No||12/31/2021|
|Raman, Jay D.||Urogen Pharma||Scientific Study or Trial||No||Current|
|Raman, Jay D.||Pacific Edge Biotechnologies||Scientific Study or Trial||No||Current|
|Raman, Jay D.||United Medical Systems, Inc.||Investment Interest||Yes||Current|
|Raman, Jay D.||Steba Biotech||Scientific Study or Trial||No||Current|
|Smith, Angela M.||PCORI||Scientific Study or Trial||No||Current|
|Smith, Angela M.||Patient-Centered Outcomes Research Institute||Scientific Study or Trial||No||Current|
|Smith, Angela M.||Merck||Consultant or Advisor||Yes||Current|
|Smith, Angela M.||Urogen||Consultant or Advisor||Yes||Current|
|Smith, Angela M.||BCAN||Scientific Study or Trial||No||Current|
|Smith, Angela M.||Ambu||Consultant or Advisor||Yes||01/31/2022|
AUA Staff have nothing to disclose.
All relevant financial disclosures have been mitigated.
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this live activity for a maximum of 8.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 8.00 AMA PRA Category 1 Credit™
- 8.00 Non-Physician Participation